In the 2016 WHO classification of CNS tumors, molecular characteristics, such as isocitrate dehydrogenase (IDH) wild-type and IDH-mutated glioblastomas, were significantly incorporated.19 For tumors lacking molecular diagnostic testing, a “not otherwise specified” (NOS) designation was permitted. This evidence concerns the gene IDH3A and central nervous system neoplasm.